Esper Launches Elevate Partner Program to Amplify Joint Opportunities
Esper Elevate is the one-stop shop for partners to boost growth opportunities
BELLEVUE, Wash.,
"Esper Elevate is more than a partner program; it's a pathway for partners to grow their businesses while delivering advanced device management solutions to their clients," said
In addition to offering robust resources, training materials, and co-marketing opportunities to ensure partner success, Esper Elevate gives partners access to Esper's industry-leading device management solutions and Esper's Partner Portal, which provides easy access to resources, selling tools, and support. Applicable Esper partners are also able to leverage Esper's Partner Control Center, which enables precision customer management, granular control over customer instances, and business insights where partners can view and manage the tenants of customers they support.
"MicroTouch is excited to partner and engage with Esper.", Said
About Esper:
Esper is on a mission to power exceptional device experiences by revolutionizing the way companies manage their device fleets. Through advanced capabilities, such as remote control & debugging, Pipelines for software deployment, Esper device SDK and APIs, Blueprints for dynamic configuration, and Seamless Provisioning, Esper is leading the market beyond standard MDM practices into the modern era of DevOps for devices and beyond. Recognized as one of Deloitte Technology Fast 500, Esper's innovative solutions support some of the world's most innovative brands in retail, hospitality, logistics, healthcare, education, and more. To learn more visit: www.esper.io.
Press contact:
Esper
Email: [email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/esper-launches-elevate-partner-program-to-amplify-joint-opportunities-302037796.html
SOURCE Esper
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Global Artist Hajime Sorayama Establishes Sorayama Hajime Estate Co., Ltd. and Announces New Management Structure
- Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) NDA Accepted by NMPA, Poised to Become World's First Approved 4-1BB-Targeting Therapy
- China's Personalized mRNA Cancer Therapy Sector Accelerates: How Far Is It From a "DeepSeek Moment"?
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share